Antibodies News and Research

RSS

Chromatin accessibility as an early marker of severe COVID-19

A new study explores the possible use of chromatin remodeling in predicting a severe clinical trajectory for COVID-19.

11 Apr 2022

Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

Researchers tested whether a subunit vaccine could generate mucosal immunity in mice and prevent SARS-CoV-2 infection and related pathology.

11 Apr 2022

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

Researchers evaluated the human antibody response to the NTD of the S protein by investigating a group of individuals who had previously been infected with SARS-CoV-2 or who had received an mRNA vaccine.

11 Apr 2022

Ultralong bovine antibody targets cryptic and conserved epitope on SARS-CoV and SARS-CoV-2

Researchers identified an ultralong bovine antibody that neutralizes SARS-CoV-2 and SARS-CoV.

11 Apr 2022

Let’s Talk about Parkinson’s

In recognition of World Parkinson's Day, we speak to Dr. Arthur Roach, Director of Research at Parkinson’s UK, about the current Parkinson's landscape.

11 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

Vaccine-induced blood clots may be the result of genetics, study finds

The rare blood clot side-effect associated with some COVID-19 vaccines could be the result of genetics, new research has found, paving the way for a potential genetic screening test.

11 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

The effect of unsuppressed HIV on T-cell response to COVID-19

A new study evaluates the impact of HIV infection on SARS-CoV-2 T-cell responses during the first and second waves of COVID-19 in South Africa.

10 Apr 2022

B-cells have significant differences in women with postpartum depression, finds study

A study published in Molecular Psychiatry is the first to look at multiple levels of biology within women with postpartum depression (PPD) to see how women with the condition differ from those without it.

10 Apr 2022

City of Hope's late-breaking clinical trial data to be presented at AACR

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year's American Association for Cancer Research Annual Meeting, which begins today.

8 Apr 2022

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

...

8 Apr 2022

Evaluating immunogenicity after BNT162b2 booster vaccination

Researchers assessed the levels of IgG and IgA antibodies in sera samples from healthcare workers before vaccination, after the first vaccine dose, after eight months, and after a booster shot.

8 Apr 2022

Role of natural immunity to SARS-CoV-2 on post-vaccination antibody responses in staff and residents of long-term care facilities

A new study collected and analyzed sera from the staff at a local long-term care facility from August to December 2020, where an outbreak occurred in September 2020.

8 Apr 2022

Improved seroprevalence and antibody response after third COVID-19 vaccination

Researchers evaluated the immunogenicity of a third COVID-19 vaccination in antibody deficient subjects.

8 Apr 2022

Neutralization potency against the Omicron variant of naturally expressed MBC-derived IgG antibodies from vaccinated individuals

Researchers have shown how the Omicron variant of the SARS-CoV-2 successfully evaded a large fraction of antibodies derived from memory B cells, giving rise to a reduced, but incomplete immune escape.

8 Apr 2022